{"title":"The role of theragnostics in oncology: an interview with Stefano Buono","authors":"S. Buono","doi":"10.2217/ije-2017-0014","DOIUrl":null,"url":null,"abstract":"Stefano Buono* speaks to Commissioning Editor, Sebastian Dennis-Beron: Stefano Buono is the Chief Executive Officer, a member of the board of directors, and a founder of Advanced Accelerator Applications (AAA). He has been responsible for overseeing AAA operations, including the development and commercialization of the current portfolio of diagnostic and therapeutic molecular nuclear medicine products, and listing AAA on Nasdaq (stock symbol: AAAP). Prior to founding the company in 2002, he worked as a physicist at the Centre for Advanced Studies, Research and Development, or CRS4, in Italy. During his 6-year tenure with CRS4, he headed a team of engineers working on different international research projects in the field of energy production and nuclear waste transmutation. Before working at CRS4, and alongside his appointment at CRS4, he worked with Physics Nobel Laureate Carlo Rubbia at The European Organization for Nuclear Research (CERN), the world’s largest research laboratory for particle physics, i...","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2017-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ije-2017-0014","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Endocrine Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/ije-2017-0014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Stefano Buono* speaks to Commissioning Editor, Sebastian Dennis-Beron: Stefano Buono is the Chief Executive Officer, a member of the board of directors, and a founder of Advanced Accelerator Applications (AAA). He has been responsible for overseeing AAA operations, including the development and commercialization of the current portfolio of diagnostic and therapeutic molecular nuclear medicine products, and listing AAA on Nasdaq (stock symbol: AAAP). Prior to founding the company in 2002, he worked as a physicist at the Centre for Advanced Studies, Research and Development, or CRS4, in Italy. During his 6-year tenure with CRS4, he headed a team of engineers working on different international research projects in the field of energy production and nuclear waste transmutation. Before working at CRS4, and alongside his appointment at CRS4, he worked with Physics Nobel Laureate Carlo Rubbia at The European Organization for Nuclear Research (CERN), the world’s largest research laboratory for particle physics, i...
期刊介绍：
International Journal of Endocrine Oncology is a quarterly, peer-reviewed journal that helps the clinician to keep up to date with best practice in this fast-moving field. The journal highlights significant advances in basic and translational research, and places them in context for future therapy. The journal presents the latest research findings in diagnosis and management of endocrine cancer, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. The journal welcomes the unsolicited submission of article proposals and original research manuscripts.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
